COSCIENS Biopharma Inc.
CSCIF
$2.08
-$0.08-3.92%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,200.70% | -4,160.78% | -1,811.79% | -814.71% | 93.54% |
| Total Depreciation and Amortization | -49.01% | -29.21% | -24.38% | -22.74% | 218.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 248.59% | 266.77% | 351.62% | 459.70% | -121.78% |
| Change in Net Operating Assets | 134.59% | -296.35% | -167.46% | -775.81% | -121.87% |
| Cash from Operations | -318.14% | -953.97% | -644.67% | -452.23% | 71.69% |
| Capital Expenditure | 37.63% | 23.23% | 9.21% | -44.76% | -3,150.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -100.00% | -100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -105.31% | 2,637.50% | 2,637.50% | 2,687.50% | 3,550.00% |
| Cash from Investing | -103.95% | -103.64% | 1,963.89% | 3,196.67% | 45,811.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 22.34% | 4.31% | -20.93% | -4.48% | -195.50% |
| Issuance of Common Stock | -- | -- | -- | -- | 1,200.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -82.43% | -- | -- | -- | -562.50% |
| Cash from Financing | 8.90% | -40.24% | -62.36% | -48.78% | -256.28% |
| Foreign Exchange rate Adjustments | 321.74% | 491.38% | -108.99% | -160.11% | -94.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -152.97% | -170.94% | 941.87% | 197.91% | 361.41% |